Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
NCT04902261Phase 2Unknown
- Sponsor
- Changhai Hospital
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in pancreatic cancer (PC), sponsored by Changhai Hospital. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04902261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04902261.